Meeting
2023 ASCO Annual Meeting
Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias.
Authors
Prithviraj Bose
The University of Texas MD Anderson Cancer Center, Houston, TX
Prithviraj Bose , Nico Gagelmann , Vikas Gupta , Donal P. McLornan , Pankit Vachhani , Haifa Kathrin Al-Ali , Haris Ali , Philipp Treskes , Sarah Buckley , Karisse Roman-Torres , Bart L. Scott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT01773187, NCT02055781
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7068)
DOI
10.1200/JCO.2023.41.16_suppl.7068
Abstract #
7068
Poster Bd #
198
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Pacritinib (PAC) vs best available therapy (BAT) in myelofibrosis (MF): Outcomes in patients (pts) with baseline (BL) thrombocytopenia.
First Author: Claire N. Harrison
Poster
2024 ASCO Annual Meeting
Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia.
First Author: Pankit Vachhani
Poster
2023 ASCO Annual Meeting
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
First Author: Helen Ajufo
Poster
2023 ASCO Annual Meeting
Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naïve patients with myelofibrosis: Updated results from XPORT-MF-034.
First Author: Haris Ali